202 related articles for article (PubMed ID: 31442331)
1. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
[TBL] [Abstract][Full Text] [Related]
2. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
[TBL] [Abstract][Full Text] [Related]
3. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
4. Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists.
Kwatra SG; Boozalis E; Huang AH; Nanni C; Khanna R; Williams KA; Semenov YR; Roberts CM; Burns RF; Krischak M; Kwatra MM
Medicines (Basel); 2019 Dec; 6(4):. PubMed ID: 31835310
[No Abstract] [Full Text] [Related]
5. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
[TBL] [Abstract][Full Text] [Related]
6. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.
Mannangatti P; Sundaramurthy S; Ramamoorthy S; Jayanthi LD
Psychopharmacology (Berl); 2017 Feb; 234(4):695-705. PubMed ID: 28013351
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
10. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Neurokinin-1 Receptor Antagonist in an Experimental Autoimmune Cystitis Model Resembling Bladder Pain Syndrome/Interstitial Cystitis.
Liu BK; Jin XW; Lu HZ; Zhang X; Zhao ZH; Shao Y
Inflammation; 2019 Feb; 42(1):246-254. PubMed ID: 30196377
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin 1 Receptor Antagonists for Pruritus.
Alam M; Buddenkotte J; Ahmad F; Steinhoff M
Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
14. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
15. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression.
Li M; Ma H; Zhang S; Peng Y; Ding L; Zhang Y; Min P
Front Endocrinol (Lausanne); 2022; 13():1077514. PubMed ID: 36686487
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
18. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
19. Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.
Fulenwider HD; Smith BM; Nichenko AS; Carpenter JM; Nennig SE; Cheng K; Rice KC; Schank JR
J Neuroinflammation; 2018 Feb; 15(1):60. PubMed ID: 29486768
[TBL] [Abstract][Full Text] [Related]
20. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]